Alcon Acquires Aerie Pharmaceuticals, Inc.

Alcon Acquires Majority Interest in Aurion Biotech, Inc.

March 26, 2025

Biotechnology

Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.

Alcon Agrees to Acquire STAAR Surgical Company

October 15, 2025

Healthcare Services

Alcon entered into a definitive merger agreement to acquire STAAR Surgical Company for $28.00 per share in cash, valuing the deal at approximately $1.5 billion. The transaction includes STAAR’s EVO family of implantable collamer lenses (EVO ICL) and is expected to close in about six to 12 months, subject to regulatory approval and STAAR shareholder approval.

Alkermes plc Acquires Avadel Pharmaceuticals plc

February 12, 2026

Pharmaceuticals

Alkermes plc completed its all-cash acquisition of Avadel Pharmaceuticals plc under an Irish High Court‑sanctioned scheme of arrangement, adding Avadel's FDA‑approved product LUMRYZ to Alkermes' commercial portfolio. The deal accelerates Alkermes' entry into the sleep medicine market, is expected to be accretive in 2026, and includes Avadel's clinical candidate valiloxybate.

Alcon to Acquire LumiThera

July 7, 2025

Medical Devices

Alcon, a leader in eye care, plans to acquire LumiThera, which develops light-based therapies for ophthalmology, including its photobiomodulation (PBM) device for treating early and intermediate dry age-related macular degeneration (AMD). The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions and a LumiThera shareholder vote.

Alcon Acquires Ivantis, Inc.

January 10, 2022

Medical Devices

Alcon has completed its acquisition of Ivantis, Inc., the developer of the Hydrus Microstent, integrating Ivantis’ manufacturing and sales employees to expand Alcon’s global surgical ophthalmology portfolio. Alcon said it will leverage its global footprint to broaden Hydrus Microstent availability and continue clinical research, including pursuing stand‑alone surgery indications in the U.S.

Alcon Agrees to Acquire LENSAR, Inc.

March 24, 2025

Medical Devices

Alcon and LENSAR entered into a definitive merger agreement under which Alcon intends to acquire LENSAR for $14.00 per share in cash, plus a contingent value right that could add up to $2.75 per share. The total potential consideration is approximately $430 million, and the deal is expected to close in mid-to-late 2025 subject to customary approvals and LENSAR stockholder approval.